Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBER Oncology Group Will Work To Create Consistent Approach To Products

Executive Summary

The Office of Cellular, Gene & Tissue Therapies' new oncology group will work to ensure coordination in approaches to oncology products throughout FDA

You may also be interested in...



FDA Oncology Therapeutics Office Planned; Drug, Biologics Units Will Merge

FDA is understood to be finalizing a plan for a new office of cancer therapeutics that would merge the current drug and biologics review groups within the Center for Drug Evaluation & Research's Office of New Drugs

FDA Oncology Therapeutics Office Planned; Drug, Biologics Units Will Merge

FDA is understood to be finalizing a plan for a new office of cancer therapeutics that would merge the current drug and biologics review groups within the Center for Drug Evaluation & Research's Office of New Drugs

FDA oncologic gene and cellular therapies

FDA Division of Oncologic Drug Products Medical Officer Steven Hirschfeld, MD/PhD, will become Oncology Group Leader in the Office of Cellular, Gene & Tissue Therapies in the Center for Biologics Evaluation & Research. Hirschfeld assumes the position starting Nov. 3...

Related Content

UsernamePublicRestriction

Register

PS042860

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel